Literature DB >> 17894000

Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors.

Roberto Gerli1, Yaniv Sherer, Elena Bartoloni Bocci, Gaetano Vaudo, Sheila Moscatelli, Yehuda Shoenfeld.   

Abstract

The risk of cardiovascular (CV) disease increases in patients with rheumatoid arthritis (RA). This is due to a number of different triggers including traditional and disease-related factors. Among established risk factors for CV disease, smoking may exert a more dangerous effect on arterial wall in RA than in the general population by a synergic effect with inflammatory processes of the disease. Although persistent inflammation and immune dysregulation of RA may contribute to favor other well-known CV risk factors, such as dyslipidemia, it is now clear that the disease itself represents an independent risk factor for CV disease by the action of RA chronic inflammatory process as well as humoral and cell-mediated immune mechanisms. There is evidence that CV risk is associated with severity and extension of the disease and it is of interest the fact that the presence of circulating anticyclic citrullinated peptide antibodies appears to be associated with stronger evidence of subclinical atherosclerosis in RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894000     DOI: 10.1196/annals.1422.038

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

1.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile?

Authors:  Banerjee Arnab; Ghosh Biswadip; Pande Arindam; Mandal Shyamash; Ghosh Anirban; Palui Rajan
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

2.  Periodontal disease in rheumatoid arthritis and Sjogren's syndrome: a modifiable risk factor for atherosclerosis?

Authors:  Satish Rachapalli
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

Review 3.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 4.  Validated methods for assessment of subclinical atherosclerosis in rheumatology.

Authors:  György Kerekes; Pál Soltész; Michael T Nurmohamed; Miguel A Gonzalez-Gay; Maurizio Turiel; Edit Végh; Yehuda Shoenfeld; Iain McInnes; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2012-02-21       Impact factor: 20.543

5.  Increased sensitivity of Apolipoprotein E knockout mice to swainsonine dependent immunomodulation.

Authors:  David W Scott; Leland L Black; Matthew O Vallejo; Janusz H Kabarowski; Rakesh P Patel
Journal:  Immunobiology       Date:  2014-03-02       Impact factor: 3.144

Review 6.  Is preclinical autoimmunity benign?: The case of cardiovascular disease.

Authors:  Darcy S Majka; Rowland W Chang
Journal:  Rheum Dis Clin North Am       Date:  2014-09-17       Impact factor: 2.670

7.  Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis.

Authors:  Matthew R Evans; Agustín Escalante; Daniel F Battafarano; Gregory L Freeman; Daniel H O'Leary; Inmaculada del Rincón
Journal:  Arthritis Rheum       Date:  2011-05

8.  Stiffening of aorta is more preferentially associated with rheumatoid arthritis than peripheral arteries.

Authors:  Yong Yang; Zhen Wang; Zihao Fu; Runrun Yang; Jia Wang; Lijun Yuan; Feng Gao; Yunyou Duan
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

Review 9.  A systematic review of the effects of dynamic exercise in rheumatoid arthritis.

Authors:  Andrew P Cairns; Joseph G McVeigh
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

Review 10.  Epigenetic control in rheumatoid arthritis synovial fibroblasts.

Authors:  Emmanuel Karouzakis; Renate E Gay; Steffen Gay; Michel Neidhart
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.